Compare · DXCM vs KRMD
DXCM vs KRMD
Side-by-side comparison of DexCom Inc. (DXCM) and KORU Medical Systems Inc. (KRMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and KRMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 161.3x KRMD ($183.3M).
- Over the past year, DXCM is down 9.5% and KRMD is up 33.4% - KRMD leads by 42.9 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 10 for KRMD).
- DXCM has more recent analyst coverage (25 ratings vs 6 for KRMD).
- Company
- DexCom Inc.
- KORU Medical Systems Inc.
- Price
- $77.53+1.22%
- $4.05+1.25%
- Market cap
- $29.57B
- $183.3M
- 1M return
- +27.88%
- -4.26%
- 1Y return
- -9.49%
- +33.44%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 26
- 10
- Recent ratings
- 25
- 6
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
KORU Medical Systems Inc.
Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest KRMD
- KORU Medical Systems Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Technology Officer Schiller Eric bought $19,562 worth of shares (5,000 units at $3.91) (SEC Form 4)
- Amendment: Chief Executive Officer Tharby Linda M bought $4,669 worth of shares (1,191 units at $3.92), increasing direct ownership by 0.19% to 620,622 units (SEC Form 4)
- Chief Executive Officer Tharby Linda M bought $1,418,481 worth of shares (1,191 units at $1,191.00), increasing direct ownership by 0.19% to 620,622 units (SEC Form 4)
- Chief Executive Officer Tharby Linda M converted options into 13,977 shares and covered exercise/tax liability with 7,326 shares, increasing direct ownership by 1% to 619,431 units (SEC Form 4) (for withholding tax)
- Chief Operating Officer Pazdan Christopher converted options into 5,327 shares and covered exercise/tax liability with 1,470 shares, increasing direct ownership by 1% to 308,988 units (SEC Form 4) to cover withholding tax
- Chief Operating Officer Pazdan Christopher bought $19,400 worth of shares (5,000 units at $3.88), increasing direct ownership by 2% to 305,131 units (SEC Form 4)
- Chief Financial Officer Adams Thomas Edward converted options into 8,193 shares and covered exercise/tax liability with 2,900 shares, increasing direct ownership by 2% to 313,440 units (SEC Form 4) to cover taxes
- Chief Financial Officer Adams Thomas Edward bought $21,248 worth of shares (5,500 units at $3.86), increasing direct ownership by 2% to 308,147 units (SEC Form 4)
- KORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress